<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Multiple sclerosis disease-modifying therapies and pregnancy washout recommendations</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Multiple sclerosis disease-modifying therapies and pregnancy washout recommendations</h1>
<div class="graphic"><div class="figure"><div class="ttl">Multiple sclerosis disease-modifying therapies and pregnancy washout recommendations</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Disease-modifying therapy</td> <td class="subtitle1">Length of disease-modifying therapy washout period per label</td> <td class="subtitle1">Length of disease-modifying therapy washout period per pharmacokinetic/<br/> pharmacodynamic placental transfer and potential risks</td> <td class="subtitle1">Characteristics</td> </tr> <tr> <td colspan="4"><strong>Self-injectable therapies (platform)</strong></td> </tr> <tr> <td class="indent1">Interferons beta (all brand formulations approved for multiple sclerosis treatments and any generic equivalents)</td> <td>No washout</td> <td>No washout</td> <td>Short half-life, lower efficacy, extensive safety data with no fetotoxicity; may be used up to conception</td> </tr> <tr> <td class="indent1">Glatiramer acetate (brand or any generic formulations)</td> <td>No washout</td> <td>No washout</td> <td>Short half-life, lower efficacy, extensive safety data with no fetotoxicity; may be used up to conception and throughout pregnancy</td> </tr> <tr class="highlight_lght_gray_text"> <td colspan="4"><strong>Oral therapies</strong></td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Teriflunomide</td> <td>Plasma levels must be &lt;0.02 mg/L, accelerated elimination can be achieved with cholestyramine</td> <td>Accelerated elimination protocol; no washout when used and plasma concentration &lt;0.02 mg/L confirmed</td> <td>Very long half-life, intermediate efficacy, animal evidence of fetotoxicity, not compatible with pregnancy</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Sphingosine-1-phosphate (S1P) receptor modulators (fingolimod, ozanimod, ponesimod, siponimod)</td> <td> <p>2 months for fingolimod</p> <p>10 days for siponimod</p> <p>3 months for ozanimod</p> 1 week for ponesimod</td> <td>2 months for fingolimod</td> <td>High efficacy, long half-life, human evidence of fetotoxicity; rebound multiple sclerosis activity after stopping this disease-modifying therapy</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Cladribine</td> <td>6 months</td> <td>4 months</td> <td>High efficacy, intermediate half-life, prolonged biologic activity after administration, no human evidence of fetotoxicity</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Dimethyl fumarate (brand and generics)</td> <td>No washout</td> <td>No washout</td> <td>Very short half-life, intermediate efficacy, no human evidence of fetotoxicity</td> </tr> <tr> <td colspan="4"><strong>Monoclonal antibodies</strong></td> </tr> <tr> <td class="indent1">Alemtuzumab</td> <td>4 months</td> <td>4 months</td> <td>Infusion, high efficacy, intermediate half-life but very prolonged biologic activity after administration</td> </tr> <tr> <td class="indent1">B-cell-depleting agents (ocrelizumab, rituximab, and ofatumumab)</td> <td>6 months</td> <td>2 months</td> <td>Infusion and self-injectable; high efficacy, intermediate half-life but prolonged biologic activity after administration; emerging safety data with pregnancy exposures reassuring</td> </tr> <tr> <td class="indent1">Natalizumab</td> <td>3 months</td> <td>No washout</td> <td>Infusion, high efficacy, intermediate half-life; reassuring emerging safety data with pregnancy exposures; rebound multiple sclerosis activity after stopping this disease-modifying therapy</td> </tr> </tbody></table></div><div class="graphic_lgnd">Washout refers to the time period during which the drug has to be stopped before conception attempts can begin.</div><div class="graphic_reference">Adapted from: Bove RM, Houtchens MK. Pregnancy management in multiple sclerosis and other demyelinating diseases. Continuum (Minneap Minn) 2022; 28:12. DOI: <a href="https://journals.lww.com/continuum/Fulltext/2022/02000/Pregnancy_Management_in_Multiple_Sclerosis_and.4.aspx?context=LatestArticles" target="_blank">10.1212/CON.0000000000001108</a>. Copyright Â© 2022 American Academy of Neurology. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id="graphicVersion">Graphic 138581 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
